Life Sciences
The Charter Group is highly involved in the life sciences technology sector, in both its M&A and capital raise activities. John Kerschen and Dale Grogan are Managing Directors of Michigan Accelerator Fund I, a venture capital fund investing in early-stage Michigan companies, focused primarily on life sciences technology.
Our depth of knowledge and involvement with key participants in this industry enable us to efficiently connect you with the right buyer, seller, or investor for your business. Here are a just few of our health science client successes. For more references, and to find out how we can help you get the best value from your transaction, please contact us.
Grand River Aseptic Manufacturing
The Charter Group was the lead sponsor of a $5 million Series B fundraising effort for Grand River Aseptic Manufacturing (GRAM). GRAM manufactures small-run, high-value clinical trial drugs that most large pharmaceutical companies cannot produce profitably.
Michigan Accelerator Fund I
MAF-1 provides a path to funding and partnerships for the commercialization of new regionally developed opportunities. The Fund invests in early stage Michigan-based companies that fall into one of four technology categories: life sciences technology, advanced manufacturing, homeland security, and alternative energy. The Fund focuses primarily on life science technology.
Intervention Insights
The Charter Group participated in a $2 million Series A capital investment. Playing an active co-lead investor role with Hopen Life Sciences and Hope River Ventures, Charter was instrumental in the completion of the funding to facilitate the commercial launch of the Intervention Insights business.
Alliant Health Care Products
Charter Capital Fund I has made a private investment in Alliant Healthcare Products in Richland, Michigan. Alliant is a veteran owned manufacturer and distributor of medical devices and equipment. The principals of The Charter Group formed Charter Capital I along with other investors to invest in Alliant.
Metabolic Solutions Development Company
Charter Capital Fund II, LLC has made a private investment in Metabolic Solutions Development Company in Kalamazoo, Michigan. MSD is a developer of innovative therapeutics to treat diabetes and related symptoms of metabolic syndrome. The principals of The Charter Group formed Charter Capital Fund II along with other investors to invest in MSD.
Welch Laboratories Inc.
A pharmaceutical processing company in Holland, Michigan, was acquired by a private investor. The Charter Group served as exclusive M&A advisors to Welch Laboratories Inc.
Vital Concepts Inc.
A medical device manufacturer in Grand Rapids, Michigan, received a secured investment from Brauer Capital LLC, an investment firm based in Atlanta, Georgia. The Charter Group served as exclusive M&A advisor to the shareholders of Vital Concepts Inc.